REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

Otsuka and Lundbeck Issue Statement on FDA Advisory Committee

REXULTI® (brexpiprazole) For Healthcare Professionals

Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval

FDA approves first drug to treat agitation symptoms associated

FDA Approves First Drug to Treat Alzheimer's Agitation

Researcher finds help for Alzheimer's-associated agitation with

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

FDA AdCom votes in favour of Lundbeck's/Otsuka's Rexulti in AAD

FDA panel backs approval of Rexulti for Alzheimer's-related agitation